Yu-Ri Choi, Ji-In Park, Seong-Sim An, Ji-Hye Choi, Mi-Na Min, Jin-Suk Kang, Jee-Eun Chung
{"title":"血液恶性肿瘤患者静脉注射对乙酰氨基酚致严重低血压的危险因素。","authors":"Yu-Ri Choi, Ji-In Park, Seong-Sim An, Ji-Hye Choi, Mi-Na Min, Jin-Suk Kang, Jee-Eun Chung","doi":"10.1002/pds.70210","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Owing to their rapid antipyretic effects and predictable pharmacokinetic properties, acetaminophen (AAP) are commonly administered intravenously to severely ill patients. However, the potential development of hypotension as a consequence of intravenous AAP administration has not been thoroughly addressed. In this study, we aimed to identify the risk factors associated with the occurrence of serious hypotension following intravenous AAP administration during fever in patients with hematologic malignancies.</p><p><strong>Methods: </strong>This retrospective study included hospitalized patients in the hemato-oncology department. Patients were evaluated for serious adverse drug reactions (ADRs) resulting from intravenous administration of AAP between January and December 2023 at a tertiary hospital. The control group comprised patients who received intravenous AAP but did not experience hypotension. After univariable analysis, multivariable analysis was performed to identify the risk factors for serious hypotension.</p><p><strong>Results: </strong>The serious hypotension group included 37 patients, while the control group had 111 patients randomized in a 1:3 ratio based on age and sex. Three risk factors were identified as increasing the likelihood of serious hypotension: body temperature prior to administration, acute kidney injury, and bacteremia. The mean arterial pressure prior to administration decreased the risk of developing serious hypotension by 0.96 times with an increase of 1 mmHg. There were no significant differences in the length of hospitalization or 90-day mortality between the two groups.</p><p><strong>Conclusions: </strong>Given that patients with hematologic malignancies and associated risk factors may develop serious hypotension that can lead to death, it is essential to closely monitor blood pressure during intravenous administration of AAP.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 9","pages":"e70210"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377936/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk Factors for Serious Hypotension Induced by Intravenous Acetaminophen in Patients With Hematologic Malignancy.\",\"authors\":\"Yu-Ri Choi, Ji-In Park, Seong-Sim An, Ji-Hye Choi, Mi-Na Min, Jin-Suk Kang, Jee-Eun Chung\",\"doi\":\"10.1002/pds.70210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Owing to their rapid antipyretic effects and predictable pharmacokinetic properties, acetaminophen (AAP) are commonly administered intravenously to severely ill patients. However, the potential development of hypotension as a consequence of intravenous AAP administration has not been thoroughly addressed. In this study, we aimed to identify the risk factors associated with the occurrence of serious hypotension following intravenous AAP administration during fever in patients with hematologic malignancies.</p><p><strong>Methods: </strong>This retrospective study included hospitalized patients in the hemato-oncology department. Patients were evaluated for serious adverse drug reactions (ADRs) resulting from intravenous administration of AAP between January and December 2023 at a tertiary hospital. The control group comprised patients who received intravenous AAP but did not experience hypotension. After univariable analysis, multivariable analysis was performed to identify the risk factors for serious hypotension.</p><p><strong>Results: </strong>The serious hypotension group included 37 patients, while the control group had 111 patients randomized in a 1:3 ratio based on age and sex. Three risk factors were identified as increasing the likelihood of serious hypotension: body temperature prior to administration, acute kidney injury, and bacteremia. The mean arterial pressure prior to administration decreased the risk of developing serious hypotension by 0.96 times with an increase of 1 mmHg. There were no significant differences in the length of hospitalization or 90-day mortality between the two groups.</p><p><strong>Conclusions: </strong>Given that patients with hematologic malignancies and associated risk factors may develop serious hypotension that can lead to death, it is essential to closely monitor blood pressure during intravenous administration of AAP.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 9\",\"pages\":\"e70210\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377936/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70210\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70210","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Risk Factors for Serious Hypotension Induced by Intravenous Acetaminophen in Patients With Hematologic Malignancy.
Purpose: Owing to their rapid antipyretic effects and predictable pharmacokinetic properties, acetaminophen (AAP) are commonly administered intravenously to severely ill patients. However, the potential development of hypotension as a consequence of intravenous AAP administration has not been thoroughly addressed. In this study, we aimed to identify the risk factors associated with the occurrence of serious hypotension following intravenous AAP administration during fever in patients with hematologic malignancies.
Methods: This retrospective study included hospitalized patients in the hemato-oncology department. Patients were evaluated for serious adverse drug reactions (ADRs) resulting from intravenous administration of AAP between January and December 2023 at a tertiary hospital. The control group comprised patients who received intravenous AAP but did not experience hypotension. After univariable analysis, multivariable analysis was performed to identify the risk factors for serious hypotension.
Results: The serious hypotension group included 37 patients, while the control group had 111 patients randomized in a 1:3 ratio based on age and sex. Three risk factors were identified as increasing the likelihood of serious hypotension: body temperature prior to administration, acute kidney injury, and bacteremia. The mean arterial pressure prior to administration decreased the risk of developing serious hypotension by 0.96 times with an increase of 1 mmHg. There were no significant differences in the length of hospitalization or 90-day mortality between the two groups.
Conclusions: Given that patients with hematologic malignancies and associated risk factors may develop serious hypotension that can lead to death, it is essential to closely monitor blood pressure during intravenous administration of AAP.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.